[1]程飞飞　刘　江　周红军.lncRNA RGMB-AS1在脑胶质瘤预后评估中的价值[J].中国临床神经外科杂志,2020,(04):199-202.[doi:10.13798/j.issn.1009-153X.2020.04.003]
　CHENG Fei-fei,LIU Jiang,ZHOU Hong-jun..Value of lncRNA RGMB-AS1 to prognosis assessment of patients with gliomas[J].,2020,(04):199-202.[doi:10.13798/j.issn.1009-153X.2020.04.003]
点击复制

lncRNA RGMB-AS1在脑胶质瘤预后评估中的价值()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年04期
页码:
199-202
栏目:
论著
出版日期:
2020-04-30

文章信息/Info

Title:
Value of lncRNA RGMB-AS1 to prognosis assessment of patients with gliomas
文章编号:
1009-153X（2020）04-0199-04
作者:
程飞飞　刘　江　周红军
401120 重庆，重庆医科大学附属第三医院（捷尔医院）神经疾病中心（程飞飞、刘　江、周红军）
Author(s):
CHENG Fei-fei;  LIU Jiang;  ZHOU Hong-jun.
Neurology Disease Center, The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing 401120, China
关键词:
脑胶质瘤; 长链非编码RNA RGMB-AS1; 预后评估; 生存期
Keywords:
Glioma;  Long chain non coding RNA;  RGMB-AS1;  Prognosis;  Survival analysis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2020.04.003
文献标志码:
A
摘要:
目的 探讨长链非编码RNA（lncRNA）RGMB-AS1在脑胶质瘤病人预后评估中的作用。方法 选取2014年9月~2017年6月经术后病理检查证实的脑胶质瘤140例（低级别64例，高级别76例），另选取颅脑损伤内减压术中切取正常脑组织25例为对照。实时荧光定量PCR法检测lncRNA RGMB-AS1的表达水平，以RGMB-AS1表达量的中位数为截断值，分为高表达组和低表达组。用Kaplan-Meier法比较总体生存期（OS）和无进展生存期（PFS），用Cox比例回归风险模型分析影响胶质瘤病人预后的因素。结果 140例胶质瘤中，lncRNA RGMB-AS1高表达70例，低表达70例。胶质瘤组织lncRNA RGMB-AS1的相对表达量明显高于对照组（P<0.05）。多因素Cox比例回归风险模型分析结果显示年龄≥50岁、术前KPS评分<80分、WHO分级Ⅲ~Ⅳ级、lncRNA RGMB-AS1高表达是胶质瘤病人PFS和OS的独立影响因素（P<0.05）。lncRNA RGMB-AS1高表达胶质瘤病人PFS和OS较低表达病人均明显缩短（P<0.05）。无论是高级别胶质瘤，还是低级别胶质瘤，lncRNA RGMB-AS1高表达病人PFS和OS较低表达病人均明显缩短（P<0.05）。结论 lncRNA RGMB-AS1表达水平与脑胶质瘤病例级别呈正相关，lncRNA RGMB-AS1高表达脑胶质瘤病人生存期较低表达病人明显缩短。这提示lncRNA RGMB-AS1表达水平可作为脑胶质瘤病人预后评估指标。
Abstract:
Objective To explore the value of long-chain non-coding RNA (lncRNA) RGMB-AS1 to the prognosis assessment of patients with gliomas. Methods The expression levels of lncRNA RGMB-AS1 were deyected in glioma tissues obtained from 140 patients with gliomas (64 of low grade, and 76 of high grade) confirmed by postoperative pathological examinations who were admitted to our hospital from September 2014 to June 2017 and in normal brain tissues obtained from 25 patients with traumatic brain injury during internal decompression (control group) by real-time fluorescence quantitative PCR. The median of lncRNA RGMB-AS1 expression level was used as the cutoff value, and then the patients with gliomas were divided into high expression group and low expression group. Kaplan-Meier method was used to compare the overall survival (OS) and progression-free survival (PFS) of ptients with gliomas, and Cox proportional regression risk model was used to analyze the factors affecting the prognosis of glioma patients. Results Of 140 glioma patients, 70 patients had high expression of lncRNA RGMB-AS1 and 70 low expression. The relative expression level of lncRNA RGMB-AS1 in glioma tissues was significantly higher than that in the control group (P<0.05). The results of multivariate Cox proportional regression risk model analysis showed that age≥50 years, preoperative KPS score<80 points, WHO grade Ⅲ~Ⅳ, and high expression of lncRNA RGMB-AS1 were independent risk factors for the PFS and OS of glioma patients (P<0.05). Regardless of the grade of glioma, the PFS and OS were significantly shorter in glioma patients with high expression of lncRNA RGMB-AS1 than those in glioma patients with lower expression of lncRNA RGMB-AS1 (P<0.05). Conclusion The expression level of lncRNA RGMB-AS1 is positively correlated with the grade of glioma. The survival time of glioma patients with high expression of lncRNA RGMB-AS1 is significantly shortened. These results suggest that lncRNA RGMB-AS1 could be used as a prognostic indicator for glioma patients.

参考文献/References:

[1] Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassi- fication to novel treatment options [J]. Semin Cancer Biol, 2018, 51: 50-58.
[2] Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function [J]. Nat Rev Genet, 2016, 17 (1): 47-62.
[3] Li P, Li J, Yang R, et al. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non- small cell lung cancer [J]. Diagn Pathol, 2015, 10(1): 63-72.
[4] Xu Z, Xi K. LncRNA RGMB-AS1 promotes laryngeal squa- mous cell carcinoma cells progression via sponging miR-22/ NLRP3 axis [J]. Biomed Pharmacother, 2019, 118: 1-11.
[5] Zhang Z, Li SY, Zhang LB. LncRNA RGMB-AS1 is activat- ed by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma [J]. Eur Rev Med Pharmacol Sci, 2018, 22(7): 1979-1986.
[6] Sheng N, Li Y, Qian R, et al. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellu- lar carcinoma [J]. Biomed Pharmacother, 2018, 98: 577- 584.
[7] Pan B, Zhao M, Wang N, et al. LncRNA RGMB-AS1 promotes glioma growth and invasion through miR-1200/ HOXB2 axis [J]. Onco Targets Ther, 2019, 12: 10107- 10114.
[8] Xu W, Liu Z, Ren H, et al. Twenty metabolic genes based signature predicts survival of glioma patients [J]. J Cancer, 2020, 11(2): 441-449.
[9] Wang L, Yu Z, Sun S, et al. Long non-coding RNAs: poten- tial molecular biomarkers for gliomas diagnosis and prog- nosis [J]. Rev Neurosci, 2017, 28(4): 375-380.
[10] Li P, Zhang G, Li J, et al. Long noncoding RNA RGMB- AS1 indicates a poor prognosis and modulates cell prolife- ration, migration and invasion in lung adenocarcinoma [J]. PLoS One, 2016, 11(3): 1-9.
[11] Zhu T, Xie P, Gao YF, et al. Nucleolar and spindle-associ- ated protein 1 is a tumor grade correlated prognosis marker for glioma patients [J]. CNS Neurosci Ther, 2018, 24(3): 178-186.

相似文献/References:

[1]付　锴　江普查　宫　睿　王　伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
　FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(04):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳　琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫　珊　徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
　YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(04):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮　夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
　LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(04):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民　褚会松　田　甜　王昆鹏　杨国军　杨立军　王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
　HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(04):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述　王　辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰　姚庆和　李晓辉　龙宇波　陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
　GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(04):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘　靖　吴立权　黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
　LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(04):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘　炎　杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明　胡新华　刘　永　陈　玖　刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]

备注/Memo

备注/Memo:
通讯作者：刘　江，E-mail：38951017@qq.com） （2020-01-07收稿，2020-03-10修回）
更新日期/Last Update: 2020-04-10